Ignite Creation Date:
2025-12-25 @ 12:12 AM
Ignite Modification Date:
2026-01-05 @ 6:07 PM
Study NCT ID:
NCT06604858
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2024-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Sponsor:
MedSIR
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-29
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-17
First Submit QC Date:
None
Study First Post Date:
2024-09-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED